Myelin Basic Protein (68-82), guinea pig |
| カタログ番号GP10006 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 98474-59-0
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Myelin Basic Protein (68-82), guinea pig,(C71H113N23O28) is a peptide with the sequence Tyr-Gly-Ser-Leu-Pro-Gln-Lys-Ser-Gln-Arg-Ser-Gln-Asp-Glu-Asn, MW= 1736.79. Myelin basic protein (MBP) is a protein believed to be important in the process of myelination of nerves in the nervous system. Knockout mice deficient in MBP showed decreased amounts of CNS myelination and have developed a progressive disorder characterized by tremors, seizures, and early death. MBP research has centered on its role in demyelinating diseases, in particular, multiple sclerosis (MS). Several studies have uncovered the role of antibodies against MBP in the pathogenesis of MS.] Some studies have linked a genetic predisposition to MS to the MBP gene, though a majority have not. Some recent work has shown that inoculating an animal with MBP to generate an immune response against it increases blood-brain barrier permeability.
References:
1. Sakamoto Y, Kitamura K, Yoshimura K, Nishijima T, Uyemura K (March 1987). "Complete amino acid sequence of POprotein in bovine peripheral nerve myelin". J. Biol. Chem. 262 (9): 4208-14.
2. Deber CM, Reynolds SJ (April 1991). "Central nervous system myelin: structure, function, and pathology". Clin. Biochem. 24 (2): 113-34.
3. Inouye H, Kirschner DA (January 1991). "Folding and function of the myelin proteins from primary sequence data". J. Neurosci. Res. 28 (1): 1-17.
4. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M (July 2003). "Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event". N. Engl. J. Med. 349 (2): 139-45.
Kinase experiment: | For each individual, the whole blood sample is typically divided into six 1 mL aliquots/tubes. Concanavalin A is added to tube 1 (positive control). Tube 2 is left untreated. Tube 3 is treated with human albumin as a negative control. Human total MBP, human MBP 104-118 fragment and guinea pig MBP (68-82) are added to tubes 4, 5 and 6, respectively. All proteins are added to a final concentration of 2 μg/mL. All experiments (incubations and flow cytometric analysis) are performed in duplicate for each subject[1]. |
Animal experiment: | Rats[2]Ten-week-old female Lewis rats are divided into the following two experimental groups: BVA-pretreated (every 3 days from 20 min before immunization) and BVA-posttreated (daily from days 10-15 after immunization) groups. Each experimental group is subdivided into the following five groups: normal [saline, subcutaneous (s.c.)+saline, s.c.], MBP [250 μg of myelin basic protein MBP (68-82), s.c.+saline, s.c., ST36 acupoint], MBP+BVA 0.25 [250 μg of MBP (68-82), s.c.+0.25 mg/kg body weight of BV, s.c., ST36 acupoint], MBP+BVA 0.8 [250 μg of MBP (68-82), s.c.+0.8 mg/kg body weight of BV, s.c., ST36 acupoint], and BVA alone [saline, s.c.+0.8 mg/kg body weight of BV, s.c., ST36 acupoint] groups. EAE is induced with an emulsion containing 250 μg of MBP (68-82) and 100 μg of Mycobacterium M. tuberculosis per mL of incomplete Freund’s adjuvant. A total of 0.2 mL of this emulsion is injected s.c. into the two hind footpads of rats except for those in the normal group and BVA alone group. Additionally, rats receive intraperitoneal (i.p.) injections of 200 ng of pertussis toxin on days 0 and 2. Rats in the normal group are treated with saline alone instead of MBP (68-82) peptide, pertussis toxin, or BVA[2]. |
References: [1]. Arneth B. Early activation of CD4+ and CD8+ T lymphocytes by myelin basic protein in subjects with MS. J Transl Med. 2015 Nov 2;13:341. | |
| Cas No. | 98474-59-0 | SDF | |
| Formula | C71H113N23O28 | M.Wt | 1736.81 |
| 溶解度 | ≥173.6mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.5758 mL | 2.8788 mL | 5.7577 mL |
| 5 mM | 0.1152 mL | 0.5758 mL | 1.1515 mL |
| 10 mM | 0.0576 mL | 0.2879 mL | 0.5758 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *